Diuretics in clinical practice. Part I: mechanisms of action, pharmacological effects and clinical indications of diuretic compounds

Bibliography

• Brater DC. Pharmacology of diuretics. Am J Med Sci 2000;319:38-50
   PubMed Web of Science ®Google Scholar
• Ellison DH. Edema and the clinical use of diuretics. In: Greenberg A, Cheung AK, Coffman TM, Falk RJ, Jennete JC, editors. Primer on kidney diseases. 4th edition. Elsevier Saunders, Philadelphia, PA; 2005. p. 136-48
   Google Scholar
• Wilcox CS. Diuretics. In: Brenner BM, editor. Brenner and Rector's: the kidney. 7th edition. Saunders, Philadelphia, PA; 2004. p. 2345-79
   Google Scholar
• Kaplan NM. Treatment of hypertension: drug therapy. In: Kaplan NM, editor. Clinical Hypertension. 9th edition. Lippincott, Williams & Wilkins, Philadelphia, PA; 2006. p. 217-310
   Google Scholar
• Portilla D, Andreoli TE. Disorders of extracellular volume. In: Feehally J, Floege J, Johnson RJ, editors. Comprehensive Clinical Nephrology. 3rd edition. Mosby Elsevier, Philadelphia, PA; 2007. p. 77-91
   Google Scholar
• Gibson DG, Marshall JC, Lockey E. Assessment of proximal tubular sodium reabsorption during water diuresis in patients with heart disease. Br Heart J 1970;32:399-405
   PubMedGoogle Scholar
• Brater DC, Kaojarern S, Chennavasin P. Pharmacodynamics of the diuretic effects of aminophylline and acetazolamide alone and combined with furosemide in normal subjects. J Pharmacol Exp Ther 1983;227:92-7
   PubMed Web of Science ®Google Scholar
• Brater DC. Diuretic therapy. N Engl J Med 1998;339:387-95
   PubMed Web of Science ®Google Scholar
• Yano I, Takayama A, Takano M, Pharmacokinetics and pharmacodynamics of acetazolamide in patients with transient intraocular pressure elevation. Eur J Clin Pharmacol 1998;54:63-8
   PubMed Web of Science ®Google Scholar
• Mazur JE, Devlin JW, Peters MJ, Single versus multiple doses of acetazolamide for metabolic alkalosis in critically ill medical patients: a randomized, double-blind trial. Crit Care Med 1999;27:1257-61
   PubMed Web of Science ®Google Scholar
• Chapron DJ, Gomolin IH, Sweeney KR. Acetazolamide blood concentrations are excessive in the elderly: propensity for acidosis and relationship to renal function. J Clin Pharmacol 1989;29:348-53
   PubMed Web of Science ®Google Scholar
• Schwenk MH, St Peter WL, Meese MG, Singhal PC. Acetazolamide toxicity and pharmacokinetics in patients receiving hemodialysis. Pharmacotherapy 1995;15:522-7
   PubMed Web of Science ®Google Scholar
• Better OS, Rubinstein I, Winaver JM, Knochel JP. Mannitol therapy revisited (1940-1997). Kidney Int 1997;52:886-94
   PubMed Web of Science ®Google Scholar
• Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med 1996;334:1448-60
   PubMed Web of Science ®Google Scholar
• Cloyd JC, Snyder BD, Cleeremans B, Mannitol pharmacokinetics and serum osmolality in dogs and humans. J Pharmacol Exp Ther 1986;236:301-6
   PubMed Web of Science ®Google Scholar
• Borges HF, Hocks J, Kjellstrand CM. Mannitol intoxication in patients with renal failure. Arch Intern Med 1982;142:63-6
   PubMed Web of Science ®Google Scholar
• Hammarlund-Udenaes M, Benet LZ. Furosemide pharmacokinetics and pharmacodynamics in health and disease--an update. J Pharmacokinet Biopharm 1989;17:1-46
   PubMedGoogle Scholar
• Seely JF, Dirks JH. Site of action of diuretic drugs. Kidney Int 1977;11:1-8
   PubMed Web of Science ®Google Scholar
• Kim GH. Long-term adaptation of renal ion transporters to chronic diuretic treatment. Am J Nephrol 2004;24:595-605
   PubMed Web of Science ®Google Scholar
• Moreno E, Tovar-Palacio C, A single nucleotide polymorphism alters the activity of the renal Na+:Cl- cotransporter and reveals a role for transmembrane segment 4 in chloride and thiazide affinity. J Biol Chem 2004;279:16553-60
   PubMed Web of Science ®Google Scholar
• Shankar SS, Brater DC. Loop diuretics: from the Na-K-2Cl transporter to clinical use. Am J Physiol Renal Physiol 2003;284:F11-21
   PubMed Web of Science ®Google Scholar
• Isenring P, Forbush B III. Ion and bumetanide binding by the Na-K-Cl cotransporter. Importance of transmembrane domains. J Biol Chem 1997;272:24556-62
   PubMed Web of Science ®Google Scholar
• Greenberg A. Diuretic complications. Am J Med Sci 2000;319:10-24
   PubMed Web of Science ®Google Scholar
• Pickkers P, Dormans TP, Russel FG, Direct vascular effects of furosemide in humans. Circulation 1997;96:1847-52
   PubMed Web of Science ®Google Scholar
• Francis GS, Siegel RM, Goldsmith SR, Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med 1985;103:1-6
   PubMed Web of Science ®Google Scholar
• Brater DC, Leinfelder J, Anderson SA. Clinical pharmacology of torasemide, a new loop diuretic. Clin Pharmacol Ther 1987;42:187-92
   PubMed Web of Science ®Google Scholar
• Ferguson JA, Sundblad KJ, Becker PK, Role of duration of diuretic effect in preventing sodium retention. Clin Pharmacol Ther 1997;62:203-8
   PubMed Web of Science ®Google Scholar
• Wilcox CS, Mitch WE, Kelly RA, Response of the kidney to furosemide. I. Effects of salt intake and renal compensation. J Lab Clin Med 1983;102:450-8
   PubMed Web of Science ®Google Scholar
• Murray MD, Haag KM, Black PK, Variable furosemide absorption and poor predictability of response in elderly patients. Pharmacotherapy 1997;17:98-106
   PubMed Web of Science ®Google Scholar
• McCrindle JL, Li Kam Wa TC, Barron W, Prescott LF. Effect of food on the absorption of frusemide and bumetanide in man. Br J Clin Pharmacol 1996;42:743-6
   PubMed Web of Science ®Google Scholar
• Kramer WG. Effect of Food on the Pharmacokinetics and Pharmacodynamics of Torsemide. Am J Ther 1995;2:499-503
   PubMedGoogle Scholar
• Murray MD, Deer MM, Ferguson JA, Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med 2001;111:513-20
   PubMed Web of Science ®Google Scholar
• Pichette V, du SP. Role of the kidneys in the metabolism of furosemide: its inhibition by probenecid. J Am Soc Nephrol 1996;7:345-9
   PubMed Web of Science ®Google Scholar
• Holazo AA, Colburn WA, Gustafson JH, Pharmacokinetics of bumetanide following intravenous, intramuscular, and oral administrations to normal subjects. J Pharm Sci 1984;73:1108-13
   PubMed Web of Science ®Google Scholar
• Wilcox CS. New insights into diuretic use in patients with chronic renal disease. J Am Soc Nephrol 2002;13:798-805
   PubMed Web of Science ®Google Scholar
• Schwartz S, Brater DC, Pound D, Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide in patients with cirrhosis. Clin Pharmacol Ther 1993;54:90-7
   PubMed Web of Science ®Google Scholar
• Voelker JR, Cartwright-Brown D, Anderson S, Comparison of loop diuretics in patients with chronic renal insufficiency. Kidney Int 1987;32:572-8
   PubMed Web of Science ®Google Scholar
• Marumo R, Kaizuma S, Nogae S, Differential upregulation of rat Na-K-Cl cotransporter, rBSC1, mRNA in the thick ascending limb of Henle in different pathological conditions. Kidney Int 1998;54:877-88
   PubMed Web of Science ®Google Scholar
• Inoue M, Okajima K, Itoh K, Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients. Kidney Int 1987;32:198-203
   PubMed Web of Science ®Google Scholar
• Kirchner KA, Voelker JR, Brater DC. Intratubular albumin blunts the response to furosemide-A mechanism for diuretic resistance in the nephrotic syndrome. J Pharmacol Exp Ther 1990;252:1097-101
   PubMed Web of Science ®Google Scholar
• Fliser D, Zurbruggen I, Mutschler E, Coadministration of albumin and furosemide in patients with the nephrotic syndrome. Kidney Int 1999;55:629-34
   PubMed Web of Science ®Google Scholar
• Chalasani N, Gorski JC, Horlander JC Sr, Effects of albumin/furosemide mixtures on responses to furosemide in hypoalbuminemic patients. J Am Soc Nephrol 2001;12:1010-6
   PubMed Web of Science ®Google Scholar
• Agarwal R, Gorski JC, Sundblad K, Brater DC. Urinary protein binding does not affect response to furosemide in patients with nephrotic syndrome. J Am Soc Nephrol 2000;11:1100-5
   PubMed Web of Science ®Google Scholar
• Holland OB, Gomez-Sanchez CE, Kuhnert LV, Antihypertensive comparison of furosemide with hydrochlorothiazide for black patients. Arch Intern Med 1979;139:1015-21
   PubMed Web of Science ®Google Scholar
• Araoye MA, Chang MY, Khatri IM, Freis ED. Furosemide compared with hydrochlorothiazide. Long-term treatment of hypertension. JAMA 1978;240:1863-6
   PubMed Web of Science ®Google Scholar
• Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc Drugs Ther 1993;7(Suppl 1):63-8
   PubMedGoogle Scholar
• Mundy GR, Guise TA. Hypercalcemia of malignancy. Am J Med 1997;103:134-45
   PubMed Web of Science ®Google Scholar
• Carroll MF, Schade DS. A practical approach to hypercalcemia. Am Fam Physician 2003;67:1959-66
   PubMed Web of Science ®Google Scholar
• Schrier RW, Lehman D, Zacherle B, Earley LE. Effect of furosemide on free water excretion in edematous patients with hyponatremia. Kidney Int 1973;3:30-4
   PubMed Web of Science ®Google Scholar
• Wagner CA, Geibel JP. Acid-base transport in the collecting duct. J Nephrol 2002;15(Suppl 5):S112-27
   Google Scholar
• Veeraveedu PT, Watanabe K, Ma M, Comparative effects of torasemide and furosemide in rats with heart failure. Biochem Pharmacol 2008;75:649-59
   PubMed Web of Science ®Google Scholar
• Diez J, Coca A, de Teresa E, TORAFIC study protocol: torasemide prolonged release versus furosemide in patients with chronic heart failure. Expert Rev Cardiovasc Ther 2009;7:897-904
   PubMedGoogle Scholar
• Beyer KH Jr, Baer JE. The site and mode of action of some sulfonamide-derived diuretics. Med Clin North Am 1975;59:735-50
   PubMed Web of Science ®Google Scholar
• Wilson FH, Kahle KT, Sabath E, Molecular pathogenesis of inherited hypertension with hyperkalemia: the Na-Cl cotransporter is inhibited by wild-type but not mutant WNK4. Proc Natl Acad Sci USA 2003;100:680-4
   PubMed Web of Science ®Google Scholar
• Simon DB, Nelson-Williams C, Bia MJ, Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nat Genet 1996;12:24-30
   PubMed Web of Science ®Google Scholar
• Lemmink HH, Knoers NV, Karolyi L, Novel mutations in the thiazide-sensitive NaCl cotransporter gene in patients with Gitelman syndrome with predominant localization to the C-terminal domain. Kidney Int 1998;54:720-30
   PubMed Web of Science ®Google Scholar
• Lajeunesse D, Brunette MG. The hypocalciuric effect of thiazides: subcellular localization of the action. Pflugers Arch 1991;417:454-62
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206-52
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, 2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
   PubMed Web of Science ®Google Scholar
• Sica DA. Current concepts of pharmacotherapy in hypertension: thiazide-type diuretics: ongoing considerations on mechanism of action. J Clin Hypertens (Greenwich) 2004;6:661-4
   PubMedGoogle Scholar
• van Brummelen P, Man in 't Veld AJ, Schalekamp MA. Hemodynamic changes during long-term thiazide treatment of essential hypertension in responders and nonresponders. Clin Pharmacol Ther 1980;27:328-36
   PubMed Web of Science ®Google Scholar
• Zhu Z, Zhu S, Liu D, Thiazide-like diuretics attenuate agonist-induced vasoconstriction by calcium desensitization linked to Rho kinase. Hypertension 2005;45:233-9
   PubMed Web of Science ®Google Scholar
• Friedman PA, Bushinsky DA. Diuretic effects on calcium metabolism. Semin Nephrol 1999;19:551-6
   PubMed Web of Science ®Google Scholar
• Knauf H, Mutschler E. Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic renal failure. J Cardiovasc Pharmacol 1995;26:394-400
   PubMed Web of Science ®Google Scholar
• Sica DA, Gehr TW. Diuretic combinations in refractory oedema states: pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet 1996;30:229-49
   PubMed Web of Science ®Google Scholar
• Uzu T, Kimura G. Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation 1999;100:1635-8
   PubMed Web of Science ®Google Scholar
• Shah SU, Anjum S, Littler WA. Use of diuretics in cardiovascular disease: (2) hypertension. Postgrad Med J 2004;80:271-6
   PubMed Web of Science ®Google Scholar
• Flack JM, Cushman WC. Evidence for the efficacy of low-dose diuretic monotherapy. Am J Med 1996;101:53S-60S
   Google Scholar
• Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 2007;49:12-26
   PubMed Web of Science ®Google Scholar
• Paton RR, Kane RE. Long-term diuretic therapy with metolazone of renal failure and the nephrotic syndrome. J Clin Pharmacol 1977;17:243-51
   PubMed Web of Science ®Google Scholar
• Brater DC. Use of diuretics in chronic renal insufficiency and nephrotic syndrome. Semin Nephrol 1988;8:333-41
   PubMed Web of Science ®Google Scholar
• Alvarez de la Rossa D, Canessa CM. Role of SGK in hormonal regulation of epithelial sodium channel in A6 cells. Am J Physiol Cell Physiol 2003;284:C404-14
   Google Scholar
• Alvarez de la Rossa D, Paunescu TG, Els WJ, Mechanisms of regulation of epithelial sodium channel by SGK1 in A6 cells. J Gen Physiol 2004;124:395-407
   PubMed Web of Science ®Google Scholar
• Snyder PM. The epithelial Na+ channel: cell surface insertion and retrieval in Na+ homeostasis and hypertension. Endocr Rev 2002;23:258-75
   PubMed Web of Science ®Google Scholar
• Palmer BF, Alpern RJ. Normal acid-base balance. In: Feehally J, Floege J, Johnson RJ, editors. Comprehensive Clinical Nephrology. 3rd edition. Philadelphia, PA: Mosby Elsevier; 2007. p. 141-57
   Google Scholar
• Verrey F, Summa V, Heitzmann D, Short-term aldosterone action on Na,K-ATPase surface expression: role of aldosterone-induced SGK1? Ann NY Acad Sci 2003;986:554-61
   PubMed Web of Science ®Google Scholar
• Gennari FJ. Hypokalemia. N Engl J Med 1998;339:451-8
   PubMed Web of Science ®Google Scholar
• Gross P, Heduschka P. Inherited disorders of sodium and water handling. In: Feehally J, Floege J, Johnson RJ, editors. Comprehensive Clinical Nephrology. 3rd edition. Mosby Elsevier, Philadelphia, PA; 2007. p. 549-59
   Google Scholar
• Jeunemaitre X, Kreft-Jais C, Chatellier G, Long-term experience of spironolactone in essential hypertension. Kidney Int Suppl 1988;26:S14-17
   Google Scholar
• Weinberger MH. The use of selective aldosterone antagonists. Curr Hypertens Rep 2004;6:342-5
   PubMed Web of Science ®Google Scholar
• Lim PO, Young WF, MacDonald TM. A review of the medical treatment of primary aldosteronism. J Hypertens 2001;19:353-61
   PubMed Web of Science ®Google Scholar
• Baxter JD, Funder JW, Apriletti JW, Webb P. Towards selectively modulating mineralocorticoid receptor function: lessons from other systems. Mol Cell Endocrinol 2004;217:151-65
   PubMed Web of Science ®Google Scholar
• Struthers AD, MacDonald TM. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 2004;61:663-70
   PubMed Web of Science ®Google Scholar
• Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney Int 2004;66:1-9
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F, Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21
   PubMed Web of Science ®Google Scholar
• Juurlink DN, Mamdani MM, Lee DS, Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543-51
   PubMed Web of Science ®Google Scholar
• Chrysostomou A, Pedagogos E, MacGregor L, Becker G. Aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006;1:256-62
   PubMed Web of Science ®Google Scholar
• Schjoedt KJ, Rossing K, Juhl TR, Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006;70:536-42
   PubMed Web of Science ®Google Scholar
• Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003;41:64-8
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Bakris GL. Resistant hypertension an overview of evaluation and treatment. J Am Coll Cardiol 2008;52:1749-57
   PubMed Web of Science ®Google Scholar
• Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003;16:925-30
   PubMed Web of Science ®Google Scholar
• Chapman N, Dobson J, Wilson S, Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007;49:839-45
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Bakris GL. State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension. J Clin Hypertens (Greenwich) 2008;10:130-9
   PubMed Web of Science ®Google Scholar
• Dontas ID, Xanthos T, Dontas I, Impact of nesiritide on renal function and mortality in patients suffering from heart failure. Cardiovasc Drugs Ther 2009;23:221-33
   PubMed Web of Science ®Google Scholar
• Colucci WS, Elkayam U, Horton DP, Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000;343:246-53
   PubMed Web of Science ®Google Scholar
• Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005;293:1900-5
   PubMed Web of Science ®Google Scholar
• Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005;111:1487-91
   PubMed Web of Science ®Google Scholar
• Ali F, Guglin M, Vaitkevicius P, Ghali JK. Therapeutic potential of vasopressin receptor antagonists. Drugs 2007;67:847-58
   PubMed Web of Science ®Google Scholar
• Arai Y, Fujimori A, Sudoh K, Sasamata M. Vasopressin receptor antagonists: potential indications and clinical results. Curr Opin Pharmacol 2007;7:124-9
   PubMed Web of Science ®Google Scholar
• Oghlakian G, Klapholz M. Vasopressin and vasopressin receptor antagonists in heart failure. Cardiol Rev 2009;17:10-5
   PubMed Web of Science ®Google Scholar
• Sedghi Y, Gaddam KK, Ventura HO. Emerging diuretics for the treatment of heart failure. Expert Opin Emerg Drugs 2009;14:195-204
   PubMed Web of Science ®Google Scholar
• Konstam MA, Gheorghiade M, Burnett JC, Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007;297:1319-31
   PubMed Web of Science ®Google Scholar